DanCann Pharma A/S: Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority
COPENHAGEN, Denmark, 29 April 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) hereby on behalf of Tetra Bio-Pharma Inc. (“Tetra”), announce that Tetra has submitted a request to the Malta Medicines Authority for a Scientific Opinion on its investigational new drug (IND) QIXLEEF for Tetra's clinical trial programs.DanCann Pharma signed February 25[th] a Letter of Intent (LOI) with Canadian Tetra Bio-Pharma Inc. concerning the exclusive distribution of the cannabinoid-based medicines Reduvo™ Adversa® and Qixleef™ in Denmark, Norway, Sweden, Finland, and Germany.